668,563 Shares in Cabaletta Bio, Inc. $CABA Bought by GSA Capital Partners LLP

Key Points

• GSA Capital Partners LLP acquired 668,563 Cabaletta Bio shares in the second quarter, worth approximately $2.08 million and representing about 0.41% of the company.
• Analyst sentiment remains mixed: five analysts rate CABA as a Buy, while one rates it Hold and one Sell. The consensus rating is “Moderate Buy,” with a target price of $15.33, though Wells Fargo recently cut its target to $3.00.
• CABA opened at $2.75, with a market capitalization of about $448 million, and reported a quarterly loss of $0.34 per share—better than the expected $0.37 loss. Cabaletta Bio is developing CAAR-T therapies for autoimmune diseases, including its lead candidate DSG3-CAART.

GSA Capital Partners LLP acquired a new position in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 668,563 shares of the company's stock, valued at approximately $2,079,000. GSA Capital Partners LLP owned approximately 0.41% of Cabaletta Bio as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently bought and sold shares of CABA. Private Advisor Group LLC grew its stake in shares of Cabaletta Bio by 22.4% during the 1st quarter. Private Advisor Group LLC now owns 18,025 shares of the company's stock worth $48,000 after purchasing an additional 3,300 shares during the period. SG Americas Securities LLC lifted its stake in shares of Cabaletta Bio by 44.0% in the fourth quarter. SG Americas Securities LLC now owns 30,629 shares of the company's stock valued at $67,000 after purchasing an additional 9,365 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of Cabaletta Bio in the first quarter valued at about $32,000. SummitTX Capital L.P. purchased a new stake in Cabaletta Bio during the first quarter worth about $34,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Cabaletta Bio during the fourth quarter worth about $34,000.

Analysts Set New Price Targets

CABA has been the topic of several recent analyst reports. Wells Fargo & Company lowered their target price on shares of Cabaletta Bio from $4.00 to $3.00 and set an "equal weight" rating on the stock in a research report on Friday. Wall Street Zen downgraded Cabaletta Bio from a "hold" rating to a "sell" rating in a research report on Saturday, June 13th. Cantor Fitzgerald reissued an "overweight" rating and issued a $30.00 target price on shares of Cabaletta Bio in a report on Monday, May 4th. Weiss Ratings restated a "sell (d-)" rating on shares of Cabaletta Bio in a research report on Friday, July 17th. Finally, Jefferies Financial Group reaffirmed a "buy" rating on shares of Cabaletta Bio in a research note on Wednesday, June 3rd. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Cabaletta Bio has a consensus rating of "Moderate Buy" and a consensus target price of $15.33.

Cabaletta Bio Stock Performance

Shares of NASDAQ CABA opened at $2.75 on Friday. The firm has a market cap of $448.39 million, a P/E ratio of -1.75 and a beta of 3.30. Cabaletta Bio, Inc. has a 1 year low of $1.40 and a 1 year high of $4.23. The firm's 50 day moving average price is $2.89 and its 200 day moving average price is $3.06.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.03. As a group, equities analysts predict that Cabaletta Bio, Inc. will post -1.34 EPS for the current year.

Cabaletta Bio Company Profile

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company's lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source